Cero Therapeutics announces progress in initiation of Phase 1 trial

CERo Therapeutics (CERO) announces the execution of an agreement with contract research organization CellCarta to manage translational assays for the Company’s upcoming Phase 1 clinical trial of CER-1236 for Acute Myeloid Leukemia. This is important progress as the Company prepares to enroll patients in the trial, as CellCarta will be responsible for key data elements, including pharmacokinetics, cytokine secretion, and target detection. CEO Chris Ehrlich commented, “We are diligently working toward enrolling patients in our Phase 1 clinical trial and each new milestones brings us closer to that event. The collection of samples and testing their chemistry is an essential aspect of the clinical trial process in liquid tumors, as they provide key data readouts beyond the safety data in a Phase 1 trial. Further, we are collaborating with multiple additional organizations to ensure that all aspects of the trial, down to logistics and transportation of samples, are in place and ready for execution.”